Abstract Featuring Titan Medical’s SPORT Surgical System Presented at the European Association of Urology Robotic Urology S...
September 06 2018 - 07:15AM
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD)
(Nasdaq: TMDI), a medical device company focused on the
design, development and commercialization of a robotic surgical
system for application in single-port minimally invasive surgery
(“MIS”), announces an abstract of a pilot study featuring the use
of its SPORT Surgical System in partial nephrectomy and
heminephrectomy procedures was presented at the European
Association of Urology Robotic Urology Section (ERUS) Annual
Meeting yesterday. The abstract, titled “Single Port Robotic
Partial and Hemi Nephrectomy Using A Novel Single Port Robotic
Platform: Pilot Study In A Pig Model” was authored by Prof.
Sebastien Crouzet, M.D., Ph.D. from the Department of Urology,
University of Lyon, France and Barbara Seeliger, M.D., Research
Fellow from Institute of Image Guided Surgery / IHU Strasbourg,
France. The pilot study was comprised of 10 procedures in a porcine
model, which demonstrated that all critical surgical tasks required
for partial nephrectomy and heminephrectomy procedures were
successfully completed using Titan’s SPORT Surgical System, with
comparable outcomes to current MIS surgical approaches and no
complications. The abstract is available for viewing here.
The 15th edition of the ERUS meeting is being
held in Marseille, France from September 5-7.
“We are thrilled to announce the presentation of
this pilot study abstract at the ERUS meeting featuring SPORT
single-port partial nephrectomy and heminephrectomy in a
preclinical setting,” said David McNally, Titan’s chief executive
officer. “Under the expert guidance of Prof. Crouzet, the
study not only demonstrated the repeatability of our single-port
approach with successful completion of critical tasks, but it also
produced comparable outcomes to current minimally invasive surgical
approaches, and notably, multi-port robotic surgery. The
repeatability, right access and demonstrated clinical value are
fundamental pillars to the success and adoption of any single-port
surgical approach. We are delighted that the SPORT system was able
to meet the challenge successfully in these urology
procedures.”
“Presentation of abstracts and publication of
research is important to Titan and part of a longer-term strategy
to build support for the SPORT system,” added Mr. McNally.
Prof. Sebastien Crouzet said, “My experience
with the SPORT Surgical System was outstanding. It is exciting to
see the repeatable and comparable results of single-port partial
nephrectomy and heminephrectomy procedures using the SPORT system,
which addresses previous limitations of single-incision approaches.
It is remarkable that the data from this 10-procedure study
indicate consistent Warm Ischemia Time (WIT) figures that are
comparable to those associated with multi-port robotic and manual
laparoscopic surgeries. Based on my significant experience
with previous single-port and multi-port surgical techniques, I am
very enthusiastic about the results of our pilot study with the
SPORT system. I am now more confident than ever in the promise that
single-port robotic technology holds for urologic surgery and
potential demand from patients seeking fewer incisions, while
maintaining superior clinical outcomes.”
About ERUS
ERUS is a premier meeting for urologists
interested in the latest technical developments in robotic surgery
and the continuous progress of urological science and practice. The
meeting’s aim is to educate the urological community on robotic
surgical techniques with the ultimate goal of improving the level
of patient care.
About Titan
Titan Medical Inc. is focused on research and
development through to the planned commercialization of
computer-assisted robotic surgical technologies for application in
minimally invasive surgery. The Company is developing the SPORT
Surgical System, a single-port robotic surgical system. The SPORT
Surgical System is comprised of a surgeon-controlled patient cart
that includes a 3D high-definition vision system and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface
to the patient cart and a 3D endoscopic view inside the patient’s
body. Titan intends to initially pursue focused surgical
indications for the SPORT Surgical System, which may include one or
more of gynecologic, urologic, colorectal or general abdominal
procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” within the meaning of applicable Canadian and U.S.
securities laws. Such statements reflect the current expectations
of management of the Company’s future growth, results of
operations, performance and business prospects and opportunities.
Wherever possible, words such as “may”, “would”, “could”, “will”,
“anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”,
“potential for” and similar expressions have been used to identify
these forward-looking statements. These statements reflect
management’s current beliefs with respect to future events and are
based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements, including,
without limitation, those listed in the “Risk Factors” section of
the Company’s Annual Information Form dated March 31, 2018 (which
may be viewed at www.sedar.com). Should one or more of these risks
or uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in the news release are based upon what management
currently believes to be reasonable assumptions, the Company cannot
assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking
statements. Except as required by law, the Company expressly
disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or otherwise.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310) 691-7100
bvoss@lhai.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From Mar 2023 to Mar 2024